Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2024-11-27 00:00:00 ET · period of report 2024-11-26 · accession 0001104659-24-123809 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-11-27 | 2024-11-26+ | PTGX | MOLINA ARTURO MD | Chief Medical Off | M - OptEx | $8.04 | +31.5K | 52.0K | +154% | +$253.5K |
| DM | 2024-11-27 | 2024-11-26+ | PTGX | MOLINA ARTURO MD | Chief Medical Off | S - Sale+OE | $44.86 | -31.5K | 46.4K | -40% | -$1.41M |
| DM | 2024-11-27 | 2024-11-26+ | PTGX | MOLINA ARTURO MD | Chief Medical Off | M - OptEx | $0.00 | -31.5K | 112.0K | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-27 | M | A | 16,000 | $8.04 | 62,444 | D | — | — | |
| 2 | Common | Common Stock | 2024-11-27 | S | D | 10,000 | $44.50 | 46,444 | D | — | — | (F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-11-26 | S | D | 5,529 | $45.60 | 46,444 | D | — | — | (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 4 | Common | Common Stock | 2024-11-27 | M | A | 10,000 | $8.04 | 56,444 | D | — | — | |
| 5 | Common | Common Stock | 2024-11-27 | S | D | 16,000 | $44.83 | 46,444 | D | — | — | (F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 6 | Common | Common Stock | 2024-11-26 | M | A | 5,529 | $8.04 | 51,973 | D | — | — | |
| 7 | Derivative | Stock Option (right to buy) | 2024-11-27 | M | D | 16,000 | $0.00 | 95,971 | D | $8.04 · — to 2032-11-15 | 16,000 Common Stock | (F4) The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. |
| 8 | Derivative | Stock Option (right to buy) | 2024-11-26 | M | D | 5,529 | $0.00 | 121,971 | D | $8.04 · — to 2032-11-15 | 5,529 Common Stock | (F4) The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. |
| 9 | Derivative | Stock Option (right to buy) | 2024-11-27 | M | D | 10,000 | $0.00 | 111,971 | D | $8.04 · — to 2032-11-15 | 10,000 Common Stock | (F4) The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. |